Kura Recieves New Patent for Tipifarnib in Lymphoma and Acute Myeloid Leukemia

Kura Oncology, Inc. (Nasdaq:KURA)  announced on 5/2/18 that the U.S. Patent and Trademark Office (USPTO) has issued a new patent protecting the company's lead product candidate, tipifarnib. U.S. patent 9,956,215, “Methods of Treating Cancer Patients with Farnesyltransferase Inhibitors,” includes multiple claims directed to the use of tipifarnib as a method of treating patients with CXCL12-expressing peripheral T-cell lymphoma (PTCL) or acute myeloid leukemia (AML).